Quest Partners LLC Increases Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Quest Partners LLC increased its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 674.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,495 shares of the company’s stock after buying an additional 3,044 shares during the period. Quest Partners LLC’s holdings in Neurocrine Biosciences were worth $403,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences in the 2nd quarter valued at $28,000. Innealta Capital LLC bought a new position in Neurocrine Biosciences during the second quarter valued at about $30,000. New Covenant Trust Company N.A. purchased a new stake in Neurocrine Biosciences during the first quarter worth about $32,000. EdgeRock Capital LLC bought a new stake in Neurocrine Biosciences in the second quarter worth about $35,000. Finally, Blue Trust Inc. boosted its stake in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock valued at $40,000 after acquiring an additional 220 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Performance

NASDAQ NBIX opened at $125.65 on Monday. Neurocrine Biosciences, Inc. has a 52-week low of $110.52 and a 52-week high of $157.98. The company has a fifty day moving average of $118.62 and a 200-day moving average of $131.94. The company has a market capitalization of $12.72 billion, a P/E ratio of 33.69 and a beta of 0.35.

Analyst Ratings Changes

NBIX has been the topic of a number of research reports. Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $131.00 to $159.00 in a report on Thursday, August 29th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Jefferies Financial Group increased their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a “buy” rating in a research note on Monday, August 19th. Robert W. Baird boosted their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.